Several studies have explored the role of PD-L1 expression or tumor mutational burden (TMB), two well-accepted biomarkers in NSCLC, on predicting immunotherapy response in SCLC, however, the result is still controversial [15–17]. This evidence concerns the gene CD274 and neoplasm.